Matthew-Wood syndrome
MONDO:0011010Matthew-Wood syndrome is a rare clinical entity including as main characteristics anophthalmia or severe microphthalmia, and pulmonary hypoplasia or aplasia.
Also known as: MCOPS9, Matthew-Wood syndrome, anophthalmia-pulmonary hypoplasia syndrome, microphthalmia syndromic type 9, microphthalmia, syndromic type 9, syndromic microphthalmia type 9, Matthew Wood syndrome, anophthalmia, clinical, with mild Facial Dysmorphism and variable malformations of the lung, heart, and diaphragm
5 clinical trials for this condition and its sub-types, 5 tagged with Matthew-Wood syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene test may guide chemo choice for tough pancreatic cancer
Knowledge-focused Recruiting nowThis pilot study aims to see if using five gene signatures from a patient's tumor can help doctors choose the best first chemotherapy for advanced pancreatic cancer. About 85 people with metastatic pancreatic cancer will have their tumor genes analyzed to pick between two standar…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC